Silexion Therapeutics Corp 8-K

What Happened
Silexion Therapeutics Corp. (SLXN) filed a Form 8‑K on February 3, 2026 under Item 7.01 (Regulation FD Disclosure) to furnish a corporate presentation prepared for use in investor meetings as part of a non‑deal roadshow. A copy of the presentation is included as Exhibit 99.1 to the filing and is incorporated by reference.

Key Details

• Filing date: February 3, 2026 (Form 8‑K, Item 7.01 — Regulation FD Disclosure).
• Document furnished: Corporate Presentation dated February 2026 (Exhibit 99.1).
• Purpose: Presentation used in meetings with investors as part of a non‑deal roadshow (management outreach without an offering).
• Exhibit/technical filing: Cover Page Interactive Data File also included in the filing (Inline XBRL).

Why It Matters
This filing gives investors access to the company’s latest corporate presentation and indicates active investor outreach by management. For retail investors, the presentation may contain updated business highlights, strategy points, clinical or operational timelines, or other information useful for evaluating the company—so reviewing Exhibit 99.1 is the direct way to see what was shared. The 8‑K itself does not report financial results or changes in management.